Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic
- Thursday, January 7, 2021, 7:03
- Finance
- Add a comment
CAMBRIDGE, Mass., Jan. 7, 2021 /PRNewswire/ — Werewolf Therapeutics, Inc., an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments, today announced the completion of its $72 million Series B financing. The proceeds from the Series B…
About the Author
adminasapcorp has written 41552 stories on this site.